Compare Stocks: CDTX, ROIV, INCY, and MRNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$120.16 -0.3%	$114.08	$81.09 ▼ $132.60	$24.36B	0.76	1.91 million shs	785,824 shs
MRNA Moderna	$63.32 -0.5%	$61.70	$22.28 ▼ $85.60	$25.28B	0.91	5.41 million shs	4.69 million shs
ROIV Roivant Sciences	$36.20 -0.2%	$33.84	$11.54 ▼ $37.00	$26.04B	1.12	5.36 million shs	4.53 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+250.01%
INCY Incyte	0.00%	-0.33%	+3.01%	+26.07%	+39.97%
MRNA Moderna	0.00%	+7.01%	+0.27%	+29.12%	+135.48%
ROIV Roivant Sciences	0.00%	-0.39%	+6.69%	+23.59%	+202.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$120.16 -0.3%	$114.08	$81.09 ▼ $132.60	$24.36B	0.76	1.91 million shs	785,824 shs
MRNA Moderna	$63.32 -0.5%	$61.70	$22.28 ▼ $85.60	$25.28B	0.91	5.41 million shs	4.69 million shs
ROIV Roivant Sciences	$36.20 -0.2%	$33.84	$11.54 ▼ $37.00	$26.04B	1.12	5.36 million shs	4.53 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+250.01%
INCY Incyte	0.00%	-0.33%	+3.01%	+26.07%	+39.97%
MRNA Moderna	0.00%	+7.01%	+0.27%	+29.12%	+135.48%
ROIV Roivant Sciences	0.00%	-0.39%	+6.69%	+23.59%	+202.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	2.30	Hold	$169.88	-23.27% Downside
INCY Incyte	2.43	Hold	$120.65	0.41% Upside
MRNA Moderna	1.88	Reduce	$42.13	-33.46% Downside
ROIV Roivant Sciences	2.83	Moderate Buy	$35.14	-2.94% Downside

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$104.00
8/10/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
8/7/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $41.00
8/7/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $42.00
8/6/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	INCY Incyte	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$121.00 ➝ $137.00
8/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$41.00 ➝ $60.00
8/3/2026	INCY Incyte	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$131.00 ➝ $155.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	$14.92 per share	N/A
INCY Incyte	$5.14B	4.74	$6.18 per share	19.44	$31.30 per share	3.84
MRNA Moderna	$1.94B	13.00	N/A	N/A	$16.93 per share	3.74
ROIV Roivant Sciences	$7.53M	3,456.93	N/A	N/A	$6.84 per share	5.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$11.78	N/A	N/A	N/A	N/A	-45.52%	-38.31%	N/A
INCY Incyte	$1.29B	$7.85	15.31	15.15	3.77	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	N/A

Latest CDTX, ROIV, INCY, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	4.62	4.62
INCY Incyte	N/A	4.59	4.51
MRNA Moderna	0.09	2.29	2.18
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
INCY Incyte	96.97%
MRNA Moderna	75.33%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
INCY Incyte	16.20%
MRNA Moderna	10.80%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	31.44 million	30.22 million	No Data
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
ROIV Roivant Sciences	860	719.27 million	655.97 million	Optionable

CDTX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

Royal Bank of Canada Decreases Position in Roivant Sciences Ltd. $ROIV

August 16 at 4:55 AM | marketbeat.com

Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV

August 16 at 3:36 AM | marketbeat.com

Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

August 15 at 3:44 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00

August 10, 2026 | americanbankingnews.com

Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV

August 9, 2026 | marketbeat.com

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

August 8, 2026 | seekingalpha.com

Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV

August 8, 2026 | marketbeat.com

Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

August 7, 2026 | marketbeat.com

Roivant Sciences Q1 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV

August 7, 2026 | marketbeat.com

Roivant outlines brepocitinib DM launch by end of September and targets cutaneous sarcoidosis Phase III data in 2028

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

August 6, 2026 | globenewswire.com

Ausblick: Roivant Sciences stellt Ergebnisse des abgelaufenen Quartals vor

August 5, 2026 | finanzen.netF

Edgestream Partners L.P. Takes Position in Roivant Sciences Ltd. $ROIV

August 4, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement System

August 4, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Grows Position in Roivant Sciences Ltd. $ROIV

August 4, 2026 | marketbeat.com

Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and MRNA Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Incyte NASDAQ:INCY

$120.16 -0.36 (-0.30%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$118.41 -1.75 (-1.46%)

As of 08/14/2026 07:40 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Moderna NASDAQ:MRNA

$63.32 -0.33 (-0.52%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$63.21 -0.11 (-0.17%)

As of 08/14/2026 07:58 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$36.20 -0.08 (-0.22%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$36.53 +0.33 (+0.90%)

As of 08/14/2026 07:34 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, ROIV, INCY, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and MRNA Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, ROIV, INCY, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and MRNA Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools